AU2020357816A1 - Modulation of microbiota compositions using targeted nucleases - Google Patents

Modulation of microbiota compositions using targeted nucleases Download PDF

Info

Publication number
AU2020357816A1
AU2020357816A1 AU2020357816A AU2020357816A AU2020357816A1 AU 2020357816 A1 AU2020357816 A1 AU 2020357816A1 AU 2020357816 A AU2020357816 A AU 2020357816A AU 2020357816 A AU2020357816 A AU 2020357816A AU 2020357816 A1 AU2020357816 A1 AU 2020357816A1
Authority
AU
Australia
Prior art keywords
crispr
nucleic acid
nuclease
sequence
chromosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020357816A
Other languages
English (en)
Inventor
Zachary Walter Beller
Gregory D. Davis
Erik Eastlund
Jeffrey Ivan Gordon
Zhigang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Aldrich Co LLC
Washington University in St Louis WUSTL
Original Assignee
Sigma Aldrich Co LLC
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co LLC, Washington University in St Louis WUSTL filed Critical Sigma Aldrich Co LLC
Publication of AU2020357816A1 publication Critical patent/AU2020357816A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/101Plasmid DNA for bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/002Vectors comprising a special translation-regulating system controllable or inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020357816A 2019-09-30 2020-09-29 Modulation of microbiota compositions using targeted nucleases Abandoned AU2020357816A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962908130P 2019-09-30 2019-09-30
US62/908,130 2019-09-30
US201962909078P 2019-10-01 2019-10-01
US62/909,078 2019-10-01
US202063052825P 2020-07-16 2020-07-16
US63/052,825 2020-07-16
PCT/US2020/053304 WO2021067291A1 (en) 2019-09-30 2020-09-29 Modulation of microbiota compositions using targeted nucleases

Publications (1)

Publication Number Publication Date
AU2020357816A1 true AU2020357816A1 (en) 2022-04-14

Family

ID=72896108

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020357816A Abandoned AU2020357816A1 (en) 2019-09-30 2020-09-29 Modulation of microbiota compositions using targeted nucleases

Country Status (10)

Country Link
US (1) US20210095273A1 (https=)
EP (1) EP4038185A1 (https=)
JP (2) JP2022549519A (https=)
KR (1) KR20220051259A (https=)
CN (1) CN114929873A (https=)
AU (1) AU2020357816A1 (https=)
BR (1) BR112022005831A2 (https=)
CA (1) CA3152931A1 (https=)
IL (1) IL291509A (https=)
WO (1) WO2021067291A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127209A1 (en) * 2019-12-17 2021-06-24 Sigma-Aldrich Co. Llc Genome editing in bacteroides
CN116004688A (zh) * 2021-10-21 2023-04-25 中国科学院深圳先进技术研究院 肠道菌拟杆菌的基因编辑方法与应用
US20250034579A1 (en) * 2021-12-07 2025-01-30 Cornell University Methods and compositions for genetically modifying human gut microbes
KR20240172712A (ko) * 2023-05-31 2024-12-10 한국생명공학연구원 아커만시아 뮤시니필라 tars를 발현 및 분비하도록 설계된 프로바이오틱스 및 이의 제조를 위한 벡터

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
JP5070051B2 (ja) * 2004-06-07 2012-11-07 クー バイオロジックス インク. 癌を治療するための細菌組成物
CA2682242A1 (en) * 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic bifidobacterium longum strain
US20110281762A1 (en) * 2010-05-13 2011-11-17 Sonnenburg Justin L High throughput screening for anaerobic microorganisms
EP3241902B1 (en) * 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
WO2015006294A2 (en) * 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
WO2015148680A1 (en) * 2014-03-25 2015-10-01 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering
US11408007B2 (en) * 2014-09-26 2022-08-09 Yale University Compositions and methods for biocontainment of microorganisms
CN107667173A (zh) * 2015-05-06 2018-02-06 斯尼普技术有限公司 改变微生物种群和改善微生物群
EP3307306A4 (en) * 2015-06-10 2019-04-24 Massachusetts Institute of Technology GENE EXPRESSION IN BACTEROIDES
JP6886142B2 (ja) * 2017-01-04 2021-06-16 国立大学法人 新潟大学 腸内細菌叢改善剤及びその使用

Also Published As

Publication number Publication date
BR112022005831A2 (pt) 2022-06-21
WO2021067291A1 (en) 2021-04-08
US20210095273A1 (en) 2021-04-01
CA3152931A1 (en) 2021-04-08
EP4038185A1 (en) 2022-08-10
KR20220051259A (ko) 2022-04-26
JP2022549519A (ja) 2022-11-25
CN114929873A (zh) 2022-08-19
IL291509A (en) 2022-05-01
JP2024116193A (ja) 2024-08-27

Similar Documents

Publication Publication Date Title
Dong et al. Exploiting a conjugative CRISPR/Cas9 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli
US20210095273A1 (en) Modulation of microbiota compositions using targeted nucleases
Nayak et al. Cas9-mediated genome editing in the methanogenic archaeon Methanosarcina acetivorans
JP2021000092A (ja) 細胞工学のための方法および遺伝システム
CN108026536A (zh) 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法
US20250354158A1 (en) Cis conjugative plasmid system
AU2003298291A1 (en) Self-containing lactobacillus strain
Chen et al. Complete nucleotide sequence of plasmid pST-III from Lactobacillus plantarum ST-III
JP2024125308A (ja) バクテロイデスにおけるゲノム編集
Álvarez-Martín et al. Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon
EP4229199A1 (en) Targeted-antibacterial-plasmids combining conjugation and crispr /cas systems and uses thereof
Steigedal et al. The Acinetobacter sp. chnB promoter together with its cognate positive regulator ChnR is an attractive new candidate for metabolic engineering applications in bacteria
JP6412865B2 (ja) ビフィドバクテリウム・ブレーベ株特異的遺伝子
Shi et al. Engineering and characterization of a symbiotic selection-marker-free vector-host system for therapeutic plasmid production
Friess et al. A CRISPRi gene regulation system for bifidobacteria
CN1989255A (zh) 降低细胞中的自发突变率
Xie et al. Exploiting the Endogenous Type II‐A CRISPR‐Cas System for Functional Engineering of Probiotic Lacticaseibacillus rhamnosus GG
Song et al. Establishment of a CRISPR interference (CRISPRi) system in Limosilactobacillus reuteri AR673
El Bakkoury et al. Bacteriocin peer selection for the production of antibiotic selection free biotherapeutic pDNA
Fontebasso Improving strategies to develop anti-Candida treatments based on the vaginal species L. gasseri: from molecular approaches to physiological analyses.
WO2024096123A1 (ja) 遺伝子が改変された微生物およびその生産方法
Disha et al. Factors and Conditions That Impact Electroporation of Clostridioides difficile Strains
Yang et al. Genomic integration and expression of the Aggregatibacter actinomycetemcomitans catalase gene in Aggregatibacter aphrophilus
Selle Functional Genomic Studies of Lactic Acid Bacteria
KR20160027582A (ko) 자살벡터를 이용하여 다제내성 균주의 변이주를 제작하는 방법

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted